ViaCyte is a leader in the emerging field of regenerative medicine. ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence.